ethyl 4-({[4-(2-butynyloxy)phenyl]sulfonyl}methyl)-1-(4-{[(3-chloroanilino)carbonyl]oxy}-2-butynyl)-4-piperidinecarboxylate | 287202-44-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯啉
• 英文名称: ethyl 4-({[4-(2-butynyloxy)phenyl]sulfonyl}methyl)-1-(4-{[(3-chloroanilino)carbonyl]oxy}-2-butynyl)-4-piperidinecarboxylate
• 英文别名: Ethyl-4-({[4-(2-butynyloxy)phenyl]sulfonyl}methyl)-1-(4-{[(3-chloroanilino)carbonyl]oxy}-2-butynyl)-4-piperidinecarboxylate；ethyl 4-[(4-but-2-ynoxyphenyl)sulfonylmethyl]-1-[4-[(3-chlorophenyl)carbamoyloxy]but-2-ynyl]piperidine-4-carboxylate
• CAS: 287202-44-2
• 化学式: C₃₀H₃₃ClN₂O₇S
• 分子量: 601.12
• InChiKey: RKJOMSWSKPRAEU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  41
• 可旋转键数：
  12
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  120
• 氢给体数：
  1
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  ethyl 4-({[4-(2-butynyloxy)phenyl]sulfonyl}methyl)-1-(4-{[(3-chloroanilino)carbonyl]oxy}-2-butynyl)-4-piperidinecarboxylate 在 甲醇 、 lithium hydroxide 作用下， 反应 3.0h， 以73%的产率得到ethyl 4-({[4-(2-butynyloxy)phenyl]sulfonyl}methyl)-1-(4-hydroxy-2-butynyl)-4-piperidinecarboxylate
  参考文献：
  名称：

  ALKYNYL CONTAINING HYDROXAMIC ACID DERIVATIVES, THEIR PREPARATION AND THEIR USE AS MATRIX METALLOPROTEINASE (MMP) INHIBITORS / TNF-ALPHA CONVERTING ENZYME (TACE) INHIBITORS

  摘要：

  公开号：

  EP1147085B1
• 作为产物：
  描述：

  4-[[[4-(2-butynyloxy)phenyl]sulfonyl]methyl]-4-piperidinecarboxylic acid ethyl ester 、 4-Chloro-2-butynyl-(3-chlorophenyl)carbamate 在 ethyl 4-({[4-(2-butynyloxy)phenyl]sulfonyl}methyl)-1-(4-{[(3-chloroanilino)carbonyl]oxy}-2-butynyl)-4-piperidinecarboxylate 作用下， 以0.27 g (64%) of the desired product was isolated as pale yellow oil的产率得到ethyl 4-({[4-(2-butynyloxy)phenyl]sulfonyl}methyl)-1-(4-{[(3-chloroanilino)carbonyl]oxy}-2-butynyl)-4-piperidinecarboxylate
  参考文献：
  名称：

  Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase/tace inhibitors

  摘要：

  这个公式的化合物对于治疗关节炎、肿瘤转移、组织溃疡、异常伤口愈合、牙周疾病、骨病、糖尿病（胰岛素抵抗）和HIV感染非常有用。

  公开号：

  US06358980B1
• 作为试剂：
  描述：

  4-[[[4-(2-butynyloxy)phenyl]sulfonyl]methyl]-4-piperidinecarboxylic acid ethyl ester 、 4-Chloro-2-butynyl-(3-chlorophenyl)carbamate 在 ethyl 4-({[4-(2-butynyloxy)phenyl]sulfonyl}methyl)-1-(4-{[(3-chloroanilino)carbonyl]oxy}-2-butynyl)-4-piperidinecarboxylate 作用下， 以0.27 g (64%) of the desired product was isolated as pale yellow oil的产率得到ethyl 4-({[4-(2-butynyloxy)phenyl]sulfonyl}methyl)-1-(4-{[(3-chloroanilino)carbonyl]oxy}-2-butynyl)-4-piperidinecarboxylate
  参考文献：
  名称：

  Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase/tace inhibitors

  摘要：

  该式化合物：在治疗关节炎、肿瘤转移、组织溃疡、异常伤口愈合、牙周疾病、骨病、糖尿病（胰岛素抵抗）和HIV感染方面有用。

  公开号：

  US06753337B2

文献信息

• US6358980B1
  申请人：——

  公开号：US6358980B1

  公开（公告）日：2002-03-19
• US6753337B2
  申请人：——

  公开号：US6753337B2

  公开（公告）日：2004-06-22
• [EN] ALKYNYL CONTAINING HYDROXAMIC ACID DERIVATIVES, THEIR PREPARATION AND THEIR USE AS MATRIX METALLOPROTEINASE (MMP) INHIBITORS/TNF-ALPHA CONVERTING ENZYME (TACE) INHIBITORS<br/>[FR] DERIVES D'ACIDE HYDROXAMIQUE ALKYNYLES, LEUR ELABORATION ET LEUR UTILISATION COMME INHIBITEURS DES METALLOPROTEINASES MATRICES OU INHIBITEURS DES TACE (ENZYMES DE CONVERSION DU FACTEUR DE NECROSE TUMORALE ALPHA)
  申请人：AMERICAN CYANAMID CO

  公开号：WO2000044723A1

  公开（公告）日：2000-08-03

  Compounds of formula (I) wherein R1 is hydrogen, aryl, heteroaryl, alkyl of 1-8 carbon atoms, alkenyl of 2-6 carbon atoms, alkynyl of 2-6 carbon atoms, cycloalkyl of 3-6 carbon atoms, or -C4-C8-cycloheteroalkyl; R2 and R3 are hydrogen, alkyl of 1-6 carbon atoms, -CN, or CCH; R8, R9, R10 and R11 are hydrogen, aryl or heteroaryl, cycloalkyl of 3-6 carbon atoms, -C4-C8-cycloheteroalkyl, alkyl of 1-18 carbon atoms, alkenyl of 2-18 carbon atoms, alkynyl of 2-18 carbon atoms; with the proviso that one of the pairs R8 and R9, R9 and R10 or R10 and R11, together with the carbon atom or atoms to which they are attached, form a cycloalkyl ring of 3-6 carbon atoms, or a -C4-C8-cycloheteroalkyl ring; R12 is hydrogen, aryl or heteroaryl, cycloalkyl of 3-6 carbon atoms; -C4-C8-cycloheteroalkyl, or alkyl of 1-6 carbon atoms; A, X are O, S, SO, SO2, NR7, or CH2; Y is aryl or heteroaryl, with the proviso that A and X are not bonded to adjacent atoms of Y; and n is 0-2; or a pharmaceutically acceptable salt thereof; useful in the treatment of arthritis, tumor metastasis, tissue ulceration, abnormal wound healing, periodontal disease, bone disease, diabetes (insulin resistance) and HIV infection.